Skip to main content
Clinical Trials/NL-OMON45948
NL-OMON45948RecruitingNot Applicable

Biomarkers in ALlergic diseases and allergen Immunotherapy - BALI

Franciscus Ziekenhuis0 sites160 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
160

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • 1. Positive Skin Prick Test (SPT) response of >= 8 mm wheal diameter and/or serum allergen-specific IgE levels higher than 0.70 kU/L to grass pollen, tree pollen and/or house dust mite (HDM) extract.
  • 2. Minimum of 18 years of age and a confirmed clinical diagnosis of allergic rhinitis.
  • 3. Clinical indication for AIT.
  • 4. Signed and dated informed consent (IC) form by a legally competent participant.

Exclusion Criteria

  • 1. History of chronic autoimmune disease (aside from asthma, atopic dermatitis or allergic rhinitis) which may interfere with results.
  • 2. Use of an antihistamines or decongestant therapy 7 days prior to screening visit.
  • 3. Prior exposure to any monoclonal antibody treatment within the past 12 months.
  • 4. Contraindication to sublingual or subcutaneous AIT.
  • 5. Current immunosuppressive treatment.
  • 6. Current pregnancy or breastfeeding, active pregnancy wish.
  • 7. Previous immunotherapy with grass pollen, tree pollen or house dust mite extract.

Investigators

Sponsor
Franciscus Ziekenhuis

Similar Trials